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Abstract
Background: DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting
immune response. However, when used as a single therapy, they are not able to drive the generated immune
response into the tumor, because of the immunosuppressive microenvironment, thus limiting their use in humans.
To enhance DNA vaccine efficacy, we combined a new poly-epitope DNA vaccine encoding melanoma tumor
associated antigens and B16F1-specific neoantigens with an oncolytic virus administered intratumorally.
Methods: Genomic analysis were performed to find specific mutations in B16F1 melanoma cells. The antigen gene
sequences were designed according to these mutations prior to the insertion in the plasmid vector. Mice were
injected with B16F1 tumor cells (n = 7–9) and therapeutically vaccinated 2, 9 and 16 days after the tumor injection.
The virus was administered intratumorally at day 10, 12 and 14. Immune cell infiltration analysis and cytokine
production were performed by flow cytometry, PCR and ELISPOT in the tumor site and in the spleen of animals, 17
days after the tumor injection.
Results: The combination of DNA vaccine and oncolytic virus significantly increased the immune activity into the
tumor. In particular, the local intratumoral viral therapy increased the NK infiltration, thus increasing the production
of different cytokines, chemokines and enzymes involved in the adaptive immune system recruitment and cytotoxic
activity. On the other side, the DNA vaccine generated antigen-specific T cells in the spleen, which migrated into
the tumor when recalled by the local viral therapy. The complementarity between these strategies explains the
dramatic tumor regression observed only in the combination group compared to all the other control groups.
Conclusions: This study explores the immunological mechanism of the combination between an oncolytic
adenovirus and a DNA vaccine against melanoma. It demonstrates that the use of a rational combination therapy
involving DNA vaccination could overcome its poor immunogenicity. In this way, it will be possible to exploit the
great potential of DNA vaccination, thus allowing a larger use in the clinic.
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Introduction
Tumor immunogenicity is not only patient specific but
inherently specific to the individual tumor itself [1].
Cancer vaccines allow the delivery of different tumor as-
sociated antigens (TAAs) and neoantigens that can be
tailored to the individual tumor [2]. This strategy would
overcome the self-tolerance associated to TAAs [1, 3]
and the issue of the cancer heterogeneity [4–7]. Indeed,
neoantigens represent ideal targets against cancer, due to
their specific expression in cancer tissue and the poten-
tial lack of side effects, and can be used in the design of
cancer vaccines [3]. In particular, cancer DNA vaccines
are stable, cost-efficient, easy to manufacture, safe and
allow the delivery of different antigens in the same plas-
mid [8]. The use of CD4 epitopes, in addition to the
CD8 epitopes, increases the DNA vaccine activity by ac-
tivating the T helper (Th) response, as already demon-
strated in preclinical essays [9–11]. Indeed, immune
recognition of mutation-derived epitopes seems to be
mostly driven by CD4 + T cells [12, 13]. However, DNA
vaccines alone fail to drive a strong immune response in
the tumor, probably due to the highly immunosuppres-
sive tumor microenvironment (TME) [8, 14]. For this
reason, DNA cancer immunization usually needs the co-
administration of other immunotherapeutic agents able
to drive the generated immune response in the tumor
border [1, 14]. Among the different combinatorial ap-
proaches, the oncolytic viruses (OVs) represent the per-
fect immunological adjuvant to lead specific T cell
response within the TME [15, 16].
OVs are biological agents that selectively infect and kill
tumor cells without causing damages in healthy cells [17,
18]. They can generate a strong immune response, includ-
ing: (i) activation of a systemic pro-inflammatory state, (ii)
attraction of cytotoxic immune cell populations to the
sites of infection to eliminate virus-containing cells, and
(iii) alarming neighboring uninfected cells of viral infec-
tion [19]. In particular, Oncolytic Adenovirus (OAd) acti-
vates the innate immune system, through the activation of
TLRs, NOD2 and other cytoplasmic sensors [20]. How-
ever, OAd per se is not able to fully eradicate highly ag-
gressive cancers, but it can be modified to be more
immunogenic [20]. We previously studied and validated a
modified OAd virus in a murine melanoma cell line,
whose genome has been modified to introduce a series of
CpG motifs [21]. The TLR9 activation that resulted from
the presence of CpG inside the virus allowed the activa-
tion of NK cells and cytokine production that were re-
sponsible of the tumor regression in nude mice [21].
We hypothesized that the combination in a no heterol-
ogous prime-boost manner of a poly-epitope and tumor-
specific pDNA vaccine with a modified CpG-rich OAd
could generate a full and specific immune response both
systemically and in the TME. In this purpose, we
designed new DNA vaccines encoding different B16F1-
TAAs and B16F1-specific neoantigens inserted in a VSV-
G gene sequence. VSV-G is a viral protein well known
to improve the immune response [22]. The efficacy of a
pVAX2 DNA vaccine encoding one CD4 and one CD8
epitope in the VSV-G sequence has been validated in
different tumor models, including B16F10 melanoma
[23]. Furthermore, the plasmid containing a single epi-
tope demonstrated a selective activation of the CD4 re-
sponse, when a CD4 epitope is encoded, or the CD8
response, when a CD8 epitope is encoded (Vandermeu-
len et al., in preparation). The advantage of delivering
neoantigens would be to overcome the immune toler-
ance associated to the TAAs.
In this study, we aimed to improve the DNA vaccine
efficacy by combining the poly-epitope DNA vaccines
(here called pDNA) and an oncolytic adenovirus sero-
type 5-CpG (here called OAd) to drive in the TME the
antigen-specific immune response generated by the
DNA vaccine. To our knowledge, this is the first time
that a DNA vaccine and an OAd are combined in a no
heterologous prime-boost manner to induce the eradica-
tion of an already established tumor. We also explored
the mechanisms and the contribution of each therapy to
the observed tumor regression, which, until now, has
been poorly explored, especially in the context of onco-
lytic virus treatment.
Results
CpG-enriched oncolytic adenovirus and poly-epitope
pDNA vaccine synergy enhanced tumor regression in
melanoma-bearing mice
To improve the efficacy of DNA vaccination, a pDNA
vaccine made of a mix of 4 plasmids encoding 2 melan-
oma TAAs and 3 neoantigens (Additional file 1) was
injected and electroporated in the tibialis muscle of mice
and combined with a CpG-enriched OAd virus [21], ad-
ministered intratumorally (IT) (Fig. 1a). Neoantigen mu-
tations have been detected in the genomic DNA (gDNA)
of the B16F1 cells at different passages to verify the sta-
bility of the mutations for the therapeutic vaccination.
These neoantigens were specifically redesigned accord-
ing to the mutations found in B16F1 cell line (Table 1).
Compared to the neoantigens described in the litera-
ture for the B16F10 cell line [12], the Cpsf3l sequence
that we found in the B16F1 cells showed some differ-
ences, as described in Table 1.
To evaluate the therapeutic efficacy of the combination,
the tumor growth was followed for each group (Fig. 1b)
and for every single mouse (Fig. 1 c-f). All the mice devel-
oped a tumor 9 days after the B16F1 cell injection. In the
pDNA+OAd group, tumor growth was significantly
slower compared with the control groups mock, pDNA or
OAd (Fig. 1b). To determine if this effect was additive or
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synergic, we used the Spector formula [24]. In particular,
we calculated the reduction in the tumor volume at day
15 (when the tumor growth curves are significantly differ-
ent) and we calculated the total standard error (SE) and
the combination index (CI), as described in Spector’s
study [24]. As our CI was >2SE, we concluded that the ef-
fect was synergic (see materials and methods). When the
vaccine was combined with the viral therapy, the tumors
never reached 300mm3 in volume until the end of the ex-
periment (day 17), as shown in Fig. 1f, while in all the
other groups, 46–100% of mice developed a bigger tumor
(red lines in Fig. 1 c-e).
pDNA and OAd increased the immune cell infiltration in
the TME; their combination allowed higher antigen-
specific T cell infiltration and NK activity
To study the mechanism underpinning the synergy between
the plasmid and the oncolytic virus therapy (pDNA+OAd
group), infiltration of immune cells was assessed in the tu-
mors of mice 17 days after the tumor injection (Fig. 2). We
first assessed the NK cells at the tumor, given their import-
ant role in innate rejection of tumor. [25] Interestingly, we
found that the total amount of NK cells was increased in all
the treated groups and, significantly, in the groups treated
with the virus (OAd and pDNA+OAd, Fig. 2a). The number
of NK cells that express the CD335 activating receptor [26]
(active NK) was significantly higher only in the combination
group compared to the mock (Fig. 2b). This data is particu-
larly interesting as it has been so far very poorly studied in
the context of oncolytic virus treatment. The number of
CD4 and CD8 adaptive immune cells also increased in the
treated groups (Fig. 2c and d), as well as the number of
IFNg-secreting CD8 T cells (Fig. 2e). As the pDNA vaccine
encoded the TRP2 melanoma antigen, the number of
TRP2-specific CD8 T cells was evaluated to test the ability
of the vaccine to produce an antigen-specific immune
Fig. 1 In vivo pDNA and OAd combination. a Therapeutic DNA vaccination protocol in combination with oncolytic virus therapy. B16F1 cells were injected
at day 0; pDNA vaccine was intramuscularly (IM) injected and electroporated 2, 9 and 16 days after tumor injection, while 109 OAd virus particles (VP) were
IT injected 10, 12 and 14 days after tumor injection. Mice were sacrificed at day 17. b Evolution of tumor volume (mm3) after B16F1 challenge as a function
of time (days) (mean ± SEM). All the groups were statistically compared to the others using two-way ANOVA, column factor (p< 0.05, n= 8). c-f Tumor
growth measurement for the single mouse and for each group of mice. In red, mice that developed a tumor >300mm3 in volume; in green, mice with a
tumor volume < 300mm3. The a, b and c letters indicate statistical differences: the presence of two different letters in two groups indicate a statistical
difference (p < 0.05) between them; the same letter in two different groups indicates the absence of a statistical difference between these two groups
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response. As TRP2 is encoded in 3 of the four plas-
mids, it was chosen as the representative epitope to
test the antigen-specific T cell infiltration. When mice
were treated with the single therapies (pDNA or
OAd), the number of TRP2-specific T cells was not
increased compared to the mock group. Only when
the two therapies were combined, the amount of
TRP2-specific T cells was found to be significantly
higher compared to all the other groups (Fig. 2f ). Dif-
ferent correlation analyses were performed to find the
contribution of the different immune populations in
the tumor growth. Almost no TRP2-specific T cells were
found in bigger tumors (mock group), while a higher infil-
tration was found in smaller tumors (Fig. 2g). Further-
more, a linear correlation (R2 > 0.90) was observed
between the number of CD8 T cells and active NK for all
the treated groups (Fig. 2h), but also between the TRP2-
specific T cells and active NK cells for the combination
group (Fig. 2i).
Cytokine involved in NK and CD8 recruitment and activity
are highly expressed in the TME of pDNA+OAd-treated
mice
To evaluate the activity and the contribution of the
NK and T cells in the TME, an evaluation of the
cytokine and perforin/granzymeB expression was per-
formed. A general increase in the cytokine expression
was observed when mice were treated with both
pDNA and OAd (Fig. 3). In particular, a higher
expression of proteins related to NK, Th1 and CTL
Fig. 2 Immune cell infiltration in the TME. a Number of total NK cells/mm3 tumor. b Number of CD335+ (active) NK cells/mm3 tumor. c Number
of non-Treg CD4 T cells/mm3 tumor. d Number of CD8 T cells/mm3 tumor. e Number of IFNg-secreting CD8 T cells/mm3 tumor. f Number of
TRP2 antigen-specific CD8 T cells/mm3 tumor. g Correlation between the tumor volume and the number of TRP2 antigen-specific CD8 T cells in
the TME. h Correlation between the number of active NK and CD8 T cells. R2 was calculated by using a linear regression analysis. i Correlation
between active NK and TRP2-specific CD8 T cells. The results in a, b, c, d, e, f and i are expressed as mean ± SEM (n = 4–6). a and b letters on the
graphs indicate significantly different results when the superscript letters are different. The annotation “a,b” indicates no significant differences
compared to a and b statistical groups. The presence of two different letters in two groups indicate a statistical difference (p < 0.05) between
them; the same letter in two different groups indicates the absence of a statistical difference between these two groups
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activity was observed, such as Granzyme B [27] (Fig.
3a), perforin [28] (Fig. 3b), TNFa [29] (Fig. 3C) and
IL2 [30] [31] (Fig. 3d). Many other interleukins were
overexpressed, such as IL15, IL12 and IL1b (Fig. 3e-g)
. Finally, an increased CCL5 expression was observed
in the OAd-treated groups, OAd and pDNA+OAd
(Fig. 3h). Generally, all the cytokines, chemokines and
enzymes were also overexpressed in the OAd group, but
without observing significant differences compared to the
mock group. Interestingly, IL10 was significantly overex-
pressed only in the OAd group (Fig. 3i). This was the only
cytokine expressed in higher amount in OAd group but
not in the pDNA+OAd group.
pDNA and OAd induced higher immune cell infiltration in
the spleen and the combination induced a greater
antigen-specific immune response
Next, we wanted to evaluate the systemic immune activ-
ity and compare it with the response in the TME. To
this end, splenocytes were collected 17 days after the
tumor challenge and analyzed (Fig. 4). All the treatments
significantly increased not only NK infiltration but also
the number of active NK in the spleen, compared to the
mock group (Fig. 4a and b). In addition to that, the
number of CD8 and non-Treg CD4 T cells was higher in
the treated groups (Fig. 4c and d). In particular, OAd
and pDNA+OAd group showed the highest number of
Fig. 3 Cytokine expression in the TME. Granzyme B (a), Perforin (b), TNFa (c), IL2 (d), IL15 (e), IL12 (f), IL1b (g), CCL5 (h), IL10 (i). All the results are
expressed as mean ± SEM (n = 4–6). a and b letters on the graphs indicate significantly different results when the superscript letters are different. The
presence of two different letters in two groups indicate a statistical difference (p < 0.05) between them; the same letter in two different groups
indicates the absence of a statistical difference between these two groups. The annotation “a,b” indicates no significant differences compared to a and
b statistical groups
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CD8 T cells (Fig. 4c). ELISPOT analysis revealed high
TRP2 specificity for pDNA and pDNA+OAd conditions,
which was significantly different compared to the other
groups (Fig. 4e and f). pDNA+OAd group showed a signifi-
cantly higher number of IFNg-secreting and TRP2-specific
splenocytes compared to pDNA alone (Fig. 4e and f).
The combination of pDNA and OAd increased the long-
term survival
Previously, we have addressed the short-term efficacy of
the combination between pDNA and OAd, showing a
significant decrease in the tumor growth and a higher
CTL infiltration and activity when the two therapies are
combined. To better understand the o, we performed a
new experiment to follow-up the long-term survival.
The vaccine and the virus have been administered fol-
lowing the same protocol used to evaluate the tumor
growth, but this time, mice were followed-up until day
45 (Fig. 5a). Our results showed that the median survival
time (MST) was significantly longer in the group treated
with pDNA and OAd. Furthermore, this combination
cured almost 30% of mice (2/7 mice), compared to 0% in
the other groups (Fig. 5b).
To exclude an unspecific systemic effect of our vac-
cine, we evaluated the efficacy of the pDNA compared
to an irrelevant plasmid. To this aim, a group of mice
Fig. 4 Immune cell analysis in the spleen. a Percentage of total NK. b Percentage of active NK. c Percentage of CD8 T cells. d Percentage of non-Treg CD4 T
cells. e-f ELISPOT analysis of the splenocytes stimulated with TRP2 peptide. All the results are expressed as mean± SEM (n = 4–6). a, b and c letters on the
graphs indicate significantly different results when the superscript letters are different. The presence of two different letters in two groups indicate a statistical
difference (p < 0.05) between them; the same letter in two different groups indicates the absence of a statistical difference between these two groups
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has been treated with a plasmid encoding for chicken
ovalbumin-derived epitopes restricted for CD4 and CD8
in the VSV-G sequence (pTOP-OVA CD4-OVA CD8).
This group did not show any differences compared to
the untreated mock group, thus supporting the contribu-
tion of the adaptive immune effect induced by the
pDNA encoding B16F1 TAAs and neoantigens.
Discussion
In the field of cancer immunotherapy, DNA vaccines
showed many promises but also failures due to their
poor immunogenicity, especially in the clinic [32]. A
renovated interest was aroused by the use of “personal-
ized” and poly-epitope DNA vaccines encoding different
TAAs and neoantigens and the possibility to combine
them with other strategies that can drive the generated
immune response in the TME [14, 33]. In the current
study, a DNA vaccine (pDNA) against B16F1 melanoma
has been tested. This pDNA was a mix of four different
plasmids globally encoding three melanoma neoantigens,
specifically designed in silico according to the B16F1
mutations (Kif18b, Cpsf3l and Pbk), and two TAAs
(TRP2 and gp100). The neoantigens Kif18b and Pbk pre-
sented the same mutations described in the literature for
B16F10 melanoma [12, 34], while the Cpsf3l neoantigen
sequence that we found in B16F1 cells was different
(Table 1). Seven amino acids were found to be mutated
in the Cpsf3l gene when compared to the wild type se-
quence. These results confirm the high mutational burden
of melanoma that many authors describe [12, 34–37].
These neoantigens were selected based on the results ob-
tained by other researchers. In particular, the mutated
form of Kif18b (K739 N) was found to be a dominant mu-
tated antigen, and mice immunized with mutated Kif18b
peptide could slow tumor growth and improve survival
[34]. Also a mutated form of Cpsf3l (D314N) has been
shown to induce a strong immune reaction preferentially
against the mutated peptide [34]. Furthermore, the three
selected neoantigens, including the mutated Pbk (V145D),
induced an immune response after vaccination with RNA.
[38] In particular, Pbk has been described as a CD8 neoan-
tigen, with a low MHC I score, which predicts the binding
affinity to the MHC I complex [38].
The antitumor activity of the pDNA vaccine was drastic-
ally improved by combining it with an OAd virus whose
genome was enriched with CpG motifs (Fig. 1) [21].
We hypothesized that the OAd virus injected IT could
activate the innate immune response locally and recruit
in the TME the adaptive immune cells generated by the
pDNA vaccine. Indeed, the IT viral therapy enhanced
the recruitment of NK cells in the TME (Fig. 2a) through
the local production of several cytokines and
Fig. 5 Evaluation of the long-term survival. a Therapeutic DNA vaccination protocol in combination with oncolytic virus therapy. B16F1 cells were
injected at day 0; pDNA vaccine was intramuscularly (IM) injected and electroporated 2, 9 and 16 days after tumor injection, while 109 OAd virus
particles (VP) were IT injected 10, 12 and 14 days after tumor injection. b Survival curves representing the percentage of alive mice (%) as a
function of time (days); MST =median survival time. Statistical analysis: Log-Rank (Mantel–Cox) test (p value < 0.05; n = 7–9). The presence of two
different letters in two groups indicate a statistical difference (p < 0.05) between them; the same letter in two different groups indicates the
absence of a statistical difference between these two groups
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chemokines, such as CCL5, IL15, IL1b, IL10, TNFa,
among others (Fig. 3) [29, 39, 40]. It has been already
demonstrated that the CpG-enriched OAd could stimu-
late the TLR9 response and that the anti-tumor immune
response was related to the NK recruitment and activity
[21]. In particular, beside the higher number of NK cells
in the TME, a significantly increased infiltration of
CD335+ NK cells (active NK cells) was observed only in
the combination group compared to the mock (Fig. 2b).
CD335 was originally identified as a receptor with the
ability to mediate the killing of tumor-transformed cells.
This receptor is also involved in the control and elimin-
ation of several pathogens and has a role in immune
homeostasis by regulating the expression of several im-
mune cell types [41]. The increased tumor infiltration of
CD335+ NK cells can be correlated with a higher gran-
zymeB, perforin and TNFa secretion in the combination
group (Fig. 3a-c), as their cytotoxic activity is mainly as-
sociated to CTL and NK cells [40, 42]. Specifically, gran-
zymeB plays a critical role in triggering apoptotic cell
death, while perforin plays an important role in NK cell-
mediated suppression of tumor initiation and metastasis
[42]. The significant increase in the number of active
NK observed only in the combination group indicates
the involvement of the pDNA in this response. Indeed,
pDNA alone significantly increased IL12 expression
compared to the mock (Fig. 3f ). Furthermore, contrarily
to the OAd group, pDNA did not increase the IL10
levels (Fig. 3i). These two ILs are important for the NK
recruitment/activity. IL12 activates NK cells to destroy a
variety of tumors in a perforin-dependent manner [40].
IL10 plays a double role in the TME: from one side, it
recruits NK cells, hence initiating immune cell infiltra-
tion. However, an excessive IL10 production can prevent
the NK activity and transform the Th response in a Th2
response [43]. The low levels of IL10 and the increased
expression of IL12 in the pDNA-treated group confirm
the ability of the DNA vaccines to shift the immune re-
sponse towards a Th1 phenotype [29, 44, 45]. IL12, as
well as TNFa, not only activate NK cells but are also se-
creted in response to the innate immune activation to
recruit the cells of the adaptive immunity [29, 45]. The
high IL12 secretion following pDNA vaccination could
be related to the Th1 switch induced by the vaccine it-
self, probably strengthen by the presence of a CD4 epi-
tope in the pDNA.
Another important cytokine in the TME was IL2. This
last is produced predominately by antigen-simulated
CD4 T cells, CD8 cells, NK and activated DCs [30]. It
plays a critical role in the differentiation of CD4 T cells
into a variety of subsets, recruits Tregs, and pro-
motes CD8 T cell and NK cytotoxicity activity [46].
In preclinical and clinical studies, IL2 is adminis-
tered in combination with cancer vaccines to
dramatically enhance their anti-tumor activity [46,
47]. It has been demonstrated that the Tregs recruit-
ment induced by IL2 could be reduced by co-
administering IL12 [48]. This association further
stimulates Th1, CTL and NK in a positive loop [47].
In the current study, the pDNA vaccine itself per-
mitted to increase the levels of IL12, which in turn
could have enhanced the antitumor properties of
IL2, contributing to the global antitumor efficacy. In-
deed, the involvement of NK, CD8 and CD4 T cell
influences the cancer immunity cycle in several as-
pects. In particular, vaccine-induced CD4 T cells
promote an inflammatory tumor microenvironment,
by producing IFNg, which improves CTL killing ac-
tivity and sensitizes tumor cells for recognition and
direct killing by cytotoxic Th1 effectors [7]. This
cycle will broad the antitumor T cell repertoire and
restore the cancer immunity cyle [7].
Finally, the higher NK activity in the TME was dir-
ectly correlated with the number of TRP-2 specific
CD8 infiltrated in the TME (Fig. 2i), which was in-
versely correlated with the tumor volume (Fig. 2g).
All these effects can explain why the NK cells are sig-
nificantly more active in the TME and the immune
response is stronger only when the two therapies are
combined.
In the spleen, both pDNA and OAd had an effect
in increasing NK, CD4 and CD8 cells (Fig. 4a, b).
In particular, antigen-stimulated splenocytes pro-
duced significantly higher amount of IFNg in the
combination group, compared to all the other
groups (Fig. 4e, f ). pDNA mainly contributed to
this effect by generating a high amount of TRP2-
specific T cells. This means that the vaccine can in-
duce the production of antigen-specific T cells sys-
temically, but it cannot drive the mounted immune
response in the TME, probably due to the immuno-
suppressive TME. The concomitant IT administration
of the virus can activate the innate immunity and re-
call the antigen-specific T cells generated by the vac-
cine into the tumor site. For this reason, we found an
increased infiltration of TRP2-specific CD8 cells only
in the TME of the combination group. This result
confirms our previous study in a mastocytoma tumor
model, where we observed that the DNA vaccine
alone failed to significantly increase the survival, due
to a poor immune T cell infiltration in the TME.
Only when it was combined with immune checkpoint
blockades the antitumor efficacy was significantly en-
hanced, due to the higher specific T cell infiltration
and activity induced by the immunocheckpoint
blockers [14].
Globally, these results explain the drastic decrease of
the tumor growth rate and the significant improved
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survival observed when pDNA was combined with the
OAd viral therapy, thus curing 30% of mice from a lethal
melanoma cell injection.
Conclusions
In this study, we demonstrated that the potency of a
poly-epitope cancer DNA vaccine against melanoma
could be dramatically enhanced by the combination with
an oncolytic virus administered in the tumor. The rea-
son of the improved efficacy was the complementarity of
the two therapies in activating the immune system. From
one side, the local IT viral therapy was able to recruit
NK innate immune cells in the TME. Therefore, differ-
ent cytokines, chemokines and enzymes involved in the
adaptive immune system recruitment and in the cyto-
toxic activity against the tumor were produced. On the
other side, pDNA was able to produce antigen-specific T
cells in the spleen, which reached the tumor when
recalled by the local viral therapy. pDNA played also an
important role in IL12 production in the TME, which
created a positive loop in cytokine production and im-
mune cell activity [47]. The global effect was the dra-
matic slowdown in the tumor growth and a significant
increase in the survival observed in the combination
group compared to all the others. Our study demon-
strates that a rational combination therapy involving
DNA vaccination could overcome its poor immunogen-
icity in the TME, leading the way to a wider use of DNA
vaccination in humans.
Materials and methods
Cell lines
B16F1 cells, a melanoma cell line from C57BL/6 mice,
were purchased from American Type Culture Collection
(ATCC; Manassas, Virginia) and cultured in MEM
complete medium, containing 10%FBS, 100 μg/ml
streptomycin and 100 U/ml penicillin (Life Technologies,
California). The human lung carcinoma cell line A549
were purchased from ATCC and cultivate in DMEM
supplemented with 10% FBS, 1% glutamine, 100 μg/ml
streptomycin and 100 U/ml penicillin.
gDNA extraction and detection of B16F1 neoantigen
mutations
B16F1 neoantigens were selected from immunogenic
B16F10 mutations described in the literature, according
to their low MHC I score, which indicates a high bind-
ing affinity, the response to RNA vaccination and the re-
active T cell subtype (CD4 or CD8) [12]. The presence
of three selected neoantigens was verified in B16F1 cell
line. Specific mutations were detected in the gDNA of
the cells at passage number 7, 16, and 27 to verify the
presence of the mutations at different time points (pas-
sage number 1 is when cells were purchased from
ATCC). gDNA was extracted using the PureLink™ Gen-
omic DNA Mini Kit (Thermo Fisher, Massachusetts).
Briefly, 20 μl of Proteinase K and 20 μl of RNAseA were
added to 200 μl of cells (106 cells) and incubated for 2
min at room temperature (RT). Then, 200 μl of the
Lysis/binding buffer were added to the cells and incu-
bate at 55 °C for 10 min, before adding 200 μl of pure
ethanol. The lysate was purified using a spin column
after 2 steps of washings with the washing buffers pro-
vided in the kit. gDNA was collected using 50 μl of elu-
tion buffer and stocked at − 20 °C, before performing the
PCR amplification (see section 5.8). Sanger sequencing
was performed by Genewiz (United Kingdom) to verify
the presence of specific mutations.
pDNA vaccine design and production
Four different plasmids encoding melanoma antigens
TRP2, Pbk, Kif18b, Cpsf3l and human gp100 were
designed (Additional file 1). Among the chosen anti-
gens, 3 are recognized by MHC class II (Gp100,
Kif18b and Cpsf3l), to stimulate CD4 T cell re-
sponse, while the others belong to MHC class I epi-
topes (TRP2 and Pbk). The antigens TRP2 and
gp100 are already known melanoma antigens [49,
50]. Their presence has been verified in B16F1 cell
line (Additional file 2). The other three are neoanti-
gens described in the literature for the B16F10
melanoma cell line [12]. They have been chosen
among the B16F10 immunogenic mutations, based
on their MHC class I binding (low score for higher
affinity) and their response after RNA and peptide
vaccination in B16F10 tumor model [12]. These
neoantigens were specifically redesigned according
to the mutations found in B16F1 cell line (Table 1).
The mutations were verified at different B16F1 cell
passages and compared with the gene expression in
the spleen of C57Bl/6 mice as a non-mutated control.
They have been cloned in a pVAX2 vector encoding
the VSV-G viral protein. Two antigens for each plas-
mid, one CD4 and one CD8, were inserted inside the
VSV-G sequence, as described in [23]. Four plasmids
were obtained: pTRP2-Gp100; pTRP2-Cpsf3l; pTRP2-
Kif18b; pGp100-Pbk (Additional file 1). The mix of
the four plasmids in a 1:1:1:1 proportion (1 μg for
each plasmid) was called pDNA. In Table 1, the
nucleotide and peptide sequences of each antigen are
shown. The underlined amino acids indicate the pres-
ence of a mutation specific in B16F1 melanoma cell
line.
As an additional control for the survival experiment,
an irrelevant plasmid has been used, encoding two OVA
epitopes in the VSV-G sequence (one CD4 and one CD8
epitopes). This plasmid has been called “pTOP-OVA
CD4-OVA CD8”.
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Virus production
Ad5D24-CpG is an OAd bearing a CpG-enriched gen-
ome in the E3 gene. It was generated, propagated, and
characterized using standard protocols, as previously de-
scribed [51].
Animal experiments and ethical permits
All animal experiments were reviewed and approved
by the Experimental Animal Committee of the Uni-
versity of Helsinki and the Provincial Government of
Southern Finland and the Belgian national regulations
guidelines in accordance with EU Directive 2010/63/
EU. The animal experiments were approved by the
ethical committee for animal care of the faculty of
medicine of the Université catholique de Louvain
(UCL/MD/010/2019). Five weeks-old C57BL/6 mice
were purchased from Envigo (Harlan, Netherlands) or
by Janvier (France). Water and food were provided ad
libitum.
Tumor implantation and tumor growth measurement
At day 0, 1 × 105 B16F1 cells diluted in 100 μl of
PBS were injected subcutaneously into the right
flank of each mouse. Tumors were measured with an
electronic digital caliper daily, starting from day 6
post tumor injection. Tumor volume was calculated
as length × width × height (in mm3). Mice were
sacrificed when the tumor volume was greater than
1500 mm3 or when they were in poor condition and
expected to die shortly. Tumors and spleens were
collected and used for further experiments. In an-
other experiment, mice survival has been followed
until the end.
pDNA vaccine injection and electroporation
Before each vaccine injection, mice were anesthetized
with ±150 μl of a solution of 10 mg/ml ketamine
(Ketalar, Pfizer, New York) and 1 mg/ml xylazine
(Sigma, St. Louis, Missouri). The left paw was
shaved using a rodent shaver (Aesculap Exacta
shaver, AgnTho’s, Sweden). Mice were injected with
1 μg of every plasmid (pDNA), or with 1 μg of
pTOP-OVA CD4-OVA CD8 irrelevant plasmid, di-
luted in 30 μl of PBS in the left tibialis cranial
muscle. The paw was then placed between 4 mm
plate caliper electrodes (BEX Co., Ltd., Japan) and elec-
troporated (200 V/cm, 8 pulses, 20ms with 500ms pause
between pulses). The pulses were delivered by a
CUY21EX electroporator (BEX Co., Ltd., Japan). The vac-
cine was administered 2, 9 and 16 days after tumor injec-
tion (Fig. 1a).
Virus injection
Before each virus injection, mice were anesthetized in an
isoflurane chamber. Then, they were injected intratumo-
rally with 109 vp CpG-rich OAd, at day 10, 12 and 14
after tumor injection. The protocol schedule of tumor,
pDNA and virus injection is shown in Fig. 1a.
Enzyme-linked ImmunoSpot (ELISPOT)
ELISpot was performed according to the manufac-
turer’s instruction (Immunospot, The ELISPOT
source, Germany). Briefly, 3 × 105 fresh splenocytes di-
luted in 100 μl CTL-Test medium (Immunospot, The
ELISPOT source, Germany) were cultured overnight
at 37 °C in anti-IFNg coated 96 well plate. For stimu-
lation, 10 ng/μl TRP2 peptide was added to the sple-
nocytes and incubated for 3 days. As positive control
for splenocyte activation, Cell Stimulation Cocktail
(Invitrogen, California) were used; PBS was used as
negative control. The development of the ELISpot
plate followed the manufacturer’s instruction (Immu-
nospot, The ELISPOT source, Germany). Spots were
counted by using an ELISPOT reader system (Immu-
nospot).
Flow cytometry analysis
NK, CD4 and CD8 T cell populations were analyzed by
FACS. Tumors and spleen were surgically removed 17
days after B16F1 cell injection and FACS analysis of tu-
mors and spleens T and NK population was performed.
To prepare single cell suspensions, cells were passed
through a 70 μm cell strainer (BD Falcon, New Jersey).
Then, they were collected, counted using an automatic
cell counter (Invitrogen, California) and washed with
PBS, before adding the blocking solution with anti-
CD16/CD32 antibody for 10 min on ice (clone 93, Biole-
gend, San Diego, California). Cells were washed and in-
cubated for 60 min at 4 °C with the following antibodies:
CD49-APC, CD335-FITC, CD11b-PerCP-Cy5.5 (for NK
detection), CD3-PerCPCy5.5, CD4-PeCy7, CD8-FITC (for
CD4 and CD8 detection). For staining with anti-FoxP3-PE
(clone FJK-16 s, eBioscience, Thermo Fisher, Waltham,
Massachusetts) or anti-IFNg-PE (clone XMG1.2, Biole-
gend, San Diego, California), cells were previously incu-
bated overnight at 4 °C with a permeabilization/fixation
solution (eBioscience™ Foxp3 / Transcription Factor Stain-
ing Buffer Set, Thermo Fisher, Waltham, Massachusetts).
Cells were then incubated with anti-CD16/CD32 antibody
for 10min on ice (Biolegend, San Diego, California),
washed and incubated for 60min at 4 °C with anti-IFNg-
PE or antiFoxP3-PE diluted in the permeabilization/fix-
ation solution. Samples were washed with PBS fixed for
10min with 4% formalin and, then, suspended in PBS.
Sample data were acquired with FACS Fortessa or FACS
Accuri (BD bioscience, Franklin Lakes, New Jersey) and
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analyzed with FlowJo software (FlowJo LLC, Ashland,
Oregon). For the tumor analysis, the number of cells was
normalized by the tumor volume (mm3).
qPCR analysis
Tumors extracted at day 17 were analyzed by qPCR.
Total RNA was isolated using TRIzol reagent (Thermo
Fisher, Waltham, Massachusetts) and phenol separation,
as previously described [14]. The quality and quantity of
RNA were evaluated using a nanospectrophotometer
(NanoDrop 2000, Thermo Fisher, Waltham, Massa-
chusetts). Extracted RNA was considered pure if the
260/280 absorbance ratio of the sample was approxi-
mately 2 and the 260/230 absorbance ratio was 1.8–
2.2. One microgram of RNA was reverse transcribed
using a first-strand synthesis system (SuperScriptTM,
Thermo Fisher, Waltham, Massachusetts) and oli-
go(dT) primers (Eurogentec, Liege, BE) according to
the supplier’s protocol. The resulting cDNA was used
as template for 40 cycles of PCR amplification. SYBR™
green real-time qPCR (GoTaq qPCR MasterMix kit,
Promega, Fitchburg, Winsconsin) was conducted on a
StepOne Plus Real-Time PCR System (Thermo Fisher,
Waltham, Massachusetts) to detect different interleu-
kins, chemokines, perforin and granzyme B. mRNA
expression in the tumors and antigen gDNA and
mRNA expression in the B16F1 cells. Analysis of the
melting curves was performed to ensure purity of
PCR products. The results were analyzed with Ste-
pOne Software V2.1. The mRNA expression of the
cytokines was calculated relative to the corresponding
expression of β-actin (reference gene) according to
the delta-delta Ct method. The results were normal-
ized compared to the mock control group. A
complete list of the primers used in this study is
shown in Table 2.
Additivity vs synergy analysis: the Spector’s formula
The synergy vs additivity analysis has been performed
by using the Spector’s formula, as described in [24]
and in Kos et al. (revised version under review).
Briefly, for an additive effect, the combination index
(CI) is in between +/− 2 times the standard error
(SE): -2SE < CI < + 2SE; while, for a synergic effect:
CI > + 2SE. The SE is defined as the derived as the
square root of the total variance divided by the num-
ber of samples. The CI is defined by the following
formula:
CI ¼ ln X1 þ ln X2 − ln X1þ 2 − ln X0 
Where:
Table 2 List of the primers used in this study
Primer name Primer sequence (5′ ➔ 3′) Amplicon length (bp)
Granzyme B For GAAGCCAGGAGATGTGTGCT 183
Rev GCACGTTTGGTCTTTGGGTC
Perforin For TCACACTGCCAGCGTAATGT 419
Rev AGGGCTGTAAGGACCGAGAT
TNFa For CATCTTCTCAAAATTCGAGTGACAA 175
Rev TGGGAGTAGACAAGGTACAACCC
IL2 For TCACATTGACACTTGTGCTCCT 191
Rev CATCCTGGGGAGTTTCAGGTTC
IL15 For TTGGGCTGTGTCAGTGTAGG 182
Rev TGCAATTCCAGGAGAAAGCAGT
IL12 For GGAAGCACGGCAGCAGAATA 180
Rev AACTTGAGGGAGAAGTAGGAATGG
IL1b For AACTGTTCCTGAACTCAACTGT 150
Rev GAGATTTGAAGCTGGATGCTCT
IL10 For GGTTGCCAAGCCTTATCGGA 115
Rev TCAGCTTCTCACCCAGGGAA
CCL5 For CTGCTGCTTTGCCTACCTCTC 149
Rev GAACCCACTTCTTCTCTGGGT
b-actin For ACTCCTATGTGGGTGACGAG 206
Rev CATCTTTTCACGGTTGGCCTTAG
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X1 ¼ mean of the effect of the control 1
in our case; the mean of the tumor volumes for pDNA aloneð Þ:
X2 ¼ mean of the effect of the control 2
in our case; the mean of the tumor volumes for OAd aloneð Þ:
X1þ 2 ¼ mean of the effect of the combination
in our case; the mean of the tumor volumes for the pDNAþOAd groupð Þ:
X0 ¼ mean of the effect of the non‐treated group
in our case the mean of the tumor volumes for the mock groupð Þ:
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 7 for Windows. Survival curves were compared
using a Mantel–Cox (log-rank) test. p-values less than
0.05 were considered statistically significant and indi-
cated with different letters on the graphs (a, b, c, d). In
particular, the presence of two different letters in two
groups indicate a statistical difference (p < 0.05) between
them; the same letter in two different groups indicates
the absence of a statistical difference between these two
groups. The annotation “a,b” indicates no significant dif-
ferences compared to a and b statistical groups.
Additional files
Additional file 1: pDNA vaccine design. pDNA vaccine design. Four
DNA vaccines encoding one CD4 epitope (in red) and one CD8 epitope
(in green). (PDF 35 kb)
Additional file 2: Expression of TRP2 and murine gp100 in B16F1
melanoma cell line. Expression of TRP2 and murine gp100 in B16F1
melanoma cell line. A) Expression of murine and human gp100 in B16F1
and B16F10 (used as a positive control). In the second line, a negative
control for the primers has been performed. B) Expression of TRP2 in B16F1,
B16F10 and B16F10-OVA cells (used as a positive control). In the last line, a
negative control for the primers has been performed. (PDF 52 kb)
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